Alltrna unlocks tRNA biology to correct disease. The company's platform incorporates AI/ML tools to learn the tRNA language and deliver diverse programmable molecules with broad therapeutic potential. Alltrna has an unprecedented opportunity to advance a single tRNA medicine to unify treatment across a wide range of diseases with the same underlying genetic mutation. Alltrna was founded in 2018 by Flagship Pioneering.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/13/23 | $109,000,000 | Series AA |
Flagship Pioneering | undisclosed |
